ACCOUNT

Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

PGe
NEWSLETTERS
PG STORE
ARCHIVES

CLASSIFIEDS

OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS

CONTACT US
ADVERTISING
CAREER OPPORTUNITIES

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 Next >

PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma

May 15, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

FARXIGA met primary endpoint in DELIVER Phase III trial, reducing risk of cardiovascular death or worsening heart failure in patients with preserved ejection fraction

May 05, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

May 05, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD Phase III Trial in Adults with Neuromyelitis Optica Spectrum Disorder

May 05, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

Imfinzi Plus Chemotherapy Granted Priority Review in the US for Patients With Locally Advanced or Metastatic Biliary Tract Cancer Based on TOPAZ-1 Phase III Trial

May 04, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ULTOMIRIS® (ravulizumab-cwvz) Approved in the US for Adults with Generalized Myasthenia Gravis

April 28, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

April 27, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

Tremelimumab accepted under Priority Review in the US for patients with unresectable liver cancer in combination with Imfinzi

April 25, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

April 20, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with previously treated HER2-mutant metastatic non-small cell lung cancer

April 19, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

April 06, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

March 24, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

March 21, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

LYNPARZA® (olaparib) reduced risk of death by 32% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer

March 16, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

February 21, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

February 14, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

January 24, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

January 18, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer

January 18, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

January 17, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen

January 17, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU

January 13, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

January 13, 2022

From AstraZeneca

Via Business Wire

Tickers AZN

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities

December 23, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

December 17, 2021

From AstraZeneca

Via Business Wire

EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

December 16, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial

December 12, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer

December 09, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

December 08, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

December 03, 2021

From AstraZeneca

Via Business Wire

Tickers AZN

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.